top of page
oa-hero.jpg

Osteoarthritis (OA) is a serious and debilitating disease with unmet needs

OA affects over 30 million people in the U.S. and is the most common cause of disability in adults

Stages of Osteoarthritis

stages-of-oa.jpg

Autologous Adipose Treatment

There is no cure for OA or any approved drugs to prevent or slow down the progression of OA. Current therapies provide only temporary pain relief. Recently, autologous adipose (fat) was used as a treatment for OA. Autologous adipose is a treatment where a patient’s own fat is harvested and injected into the affected joints. The results demonstrated improvements in pain and functionality with the potential to delay OA progression. However, autologous adipose has drawbacks that patients must consider.

Autologous Adipose Drawbacks
​

  • Not available on demand: Lipoaspiration, a fat collection surgery, is required for every patient
     

  • Unpredictable results: Due to the lack of standardized fat preparation and variations in tissue quality among patients
     

  • Retreatment challenge: Lipoaspiration is required each time

autologous-adipose-treatment-illustration.jpg
brc-oa-vial.jpg
BRC-OA has the potential to:

  • Stop inflammation in the joint helping with pain reduction & improvement of functionality

  • Mobilize endogenous stem cells in the joint assisting with cartilage repair & delaying OA progression

BRC-OA*, A Novel Human Adipose Tissue Allograft Therapy in Development for OA

BRC-OA has OA modifying potential without the limits of autologous adipose including:
​

  • Available on-demand without quantity limitation

  • Prolonged storage

  • Minimally invasive injection

  • No matching or immunosuppression required

  • Robust manufacturing process & testing to ensure quality

If you are interested in participating in the clinical trial, please contact Molly Saunders (msaunders@britecyte.com) for more information.

​​

*Patent pending

A New OA Therapy

The U.S. Food and Drug Administration (FDA) has cleared Britecyte’s Investigational New Drug (IND) application for BRC-OA for the treatment of knee OA, enabling the Company to initiate its Phase 1/2a clinical trial in the U.S.

bottom of page